Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Envelop VLP Control protein-VLP

Cette protéine VLP est produite dans HEK-293 Cells.
N° du produit ABIN7448174

Aperçu rapide pour Envelop VLP Control protein-VLP (ABIN7448174)

Antigène

Envelop VLP Control

Type de proteíne

VLP

Origine

Humain

Source

HEK-293 Cells

Application

ELISA, Functional Studies (Func), Immunogen (Imm), Surface Plasmon Resonance (SPR)

Pureté

> 95 % as determined by HPLC
  • Fonction

    Human Envelop VLP Control

    Attributs du produit

    Recombinant Human Envelop VLP Control is expressed from HEK293.

    Stérilité

    0.22 μm filtered

    niveau d'endotoxine

    Less than 1 EU per μg by the LAL method.
  • Vous souhaitez d'autres options pour ce Protein ?

    !
    Découvrez nos protéines personnalisées prédéfinies et nos services de protéines sur mesure !

    Votre projet nécessite-t-il une personnalisation supplémentaire ? Contactez-nous et découvrez nos solutions protéiques sur mesure

  • Indications d'application

    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA

    Commentaires

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Supplied as 0.22 μm filtered solution in PBS ( pH 7.4).

    Stock

    -80 °C

    Stockage commentaire

    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

    Date de péremption

    12 months
  • Antigène

    Envelop VLP Control

    Sujet

    VLPs are formed by spontaneous interaction between one or more viral structural capsid proteins to form the final structure. VLPs are structurally and visually similar to live viruses but lack either a complete virus genome or lack the entire virus genome[1]. The envelop VLP control is pure viral protein particle structure without the displayed proteins, which can be used as control for the activity assay of the envelope VLP display proteins.
Vous êtes ici:
Chat with us!